NEJM — Sirolimus-Eluting versus Uncoated Stents in Acute Myocardial Infarction

The stent debate continues.
NEJM — Sirolimus-Eluting versus Uncoated Stents in Acute Myocardial Infarction
Background Sirolimus-eluting stents reduce rates of restenosis and reintervention, as compared with uncoated stents. Data are limited regarding the safety and efficacy of such stents in primary percutaneous coronary intervention (PCI) for acute myocardial infarction with ST-segment elevation.

Bookmark and Share

Related posts:

  1. FDA Statement on Coronary Drug-Eluting Stents
  2. Abbott Begins Early International Launch of XIENCE™ Everolimus Eluting Coronary Stent System
  3. Clinical and Angiographic Outcomes After Placement of Multiple Overlapping Drug-Eluting Stents in Diffuse Coronary Lesions
  4. J&J – Conor CoStar(r) Clinical Trial Stent Stopped
  5. Do drug eluting stents DES increase deaths?

Tags:

Post Author

This post was written by Editor who has written 96 posts on the international medical market place.

Trackbacks/Pingbacks

  1. the international medical market place » FDA Statement on Coronary Drug-Eluting Stents - September 16, 2006

    [...] contact _uacct = “UA-312296-3″; urchinTracker(); « NEJM — Sirolimus-Eluting versus Uncoated Stents in Acute Myocardial Infarction 16.09.06 [...]

  2. the international medical market place » Abbott Begins Early International Launch of XIENCE™ Everolimus Eluting Coronary Stent System - October 5, 2006

    [...] More here. By admin Feedbacks on this entry via RSS 2.0 Please leave a Comment or discuss via Trackback! Comments Please Leave aComment! [...]

  3. the international medical market place » Abbott Begins Early International Launch of XIENCE™ Everolimus Eluting Coronary Stent System - October 5, 2006

    [...] post here By admin Feedbacks on this entry via RSS 2.0 Please leave a Comment or discuss via Trackback! Comments Please Leave aComment! [...]

  4. Abbott Begins Early International Launch of XIENCE™ Everolimus Eluting Coronary Stent System — the international medical market place - November 14, 2007

    [...] significant superiority to the TAXUS® paclitaxel-eluting coronary stent system”. Related post here [?] Share [...]

Leave a Reply